S&P 500 climbs to record high as in-line inflation data point to Fed rate cut
BOSTON/SAN DIEGO - Rapport Therapeutics, Inc. (NASDAQ:RAPP), a $560 million market cap biotech company whose shares have surged 47% over the past six months despite a recent 13% weekly decline, will host a conference call and webcast on September 8, 2025, to announce topline results from its Phase 2a trial of RAP-219 in patients with drug-resistant focal onset seizures, the company said in a press release.
The clinical-stage biotechnology company, which focuses on developing small molecule precision medicines for neurological and psychiatric disorders, will present the findings at 8:00 am ET. According to InvestingPro data, analysts maintain a Strong Buy consensus on RAPP, with 8 additional key insights available to subscribers.
RAP-219 is Rapport’s lead investigational drug, designed to achieve neuroanatomical specificity by selectively targeting receptor associated proteins (RAPs) expressed in specific brain regions. The company is evaluating the compound not only for epilepsy but also for bipolar mania and diabetic peripheral neuropathic pain.
Rapport’s approach leverages its RAP technology platform, which the company states enables the development of precision small molecule candidates for neurological conditions.
Investors and other interested parties can access the conference call through a webcast link or by dialing (800) 715-9871 in the U.S. or (646) 307-1963 for international locations, using conference ID 4762775. A replay will be available on the company’s website for 90 days following the call.
Rapport Therapeutics is also advancing additional preclinical and discovery-stage programs targeting chronic pain and hearing disorders.
In other recent news, Rapport Therapeutics has seen its stock rating reiterated by multiple firms. JMP Securities maintained its Market Outperform rating with a price target of $28, expressing increased confidence in the potential positive results for RAP-219 in focal epilepsy, expected in September. Similarly, Citizens JMP reiterated its Market Outperform rating, also with a $28 price target, highlighting the upcoming top-line results from a Phase 2a trial for RAP-219 as a significant catalyst. TD Cowen also reaffirmed its Buy rating after an investor dinner featuring a key opinion leader in epileptology, who showed strong optimism about RAP-219. These developments indicate a consistent positive outlook from analysts regarding Rapport Therapeutics’ ongoing clinical trials.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.